Targeted HDAC8 inhibition with non-hydroxamate [1,2,4]triazolo[4,3-a] quinoline compounds

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Cancer Research

Background:

• Histone deacetylase 8 (HDAC8) plays a crucial role in gene expression and tumor development, particularly in neuroblastoma.
• Targeting HDAC8 is a promising strategy for developing novel cancer therapies.

Purpose of the Study:

• To design, synthesize, and evaluate novel substituted [1,2,4]Triazolo[4,3-a]quinoline derivatives as potential HDAC8 inhibitors.
• To investigate the molecular interactions and biological efficacy of these compounds against neuroblastoma.

Main Methods:

• Synthesis of novel [1,2,4]Triazolo[4,3-a]quinoline derivatives.
• Molecular docking and molecular dynamics simulations to assess binding interactions with HDAC8.
• In vitro assays using neuroblastoma cell lines (IMR-32) and other cancer/normal cell lines (HCT116, MCF7, HEK293).
• Cell cycle, apoptosis, colony formation, cell migration, and SMC3 acetylation assays.

Main Results:

• Novel compounds demonstrated potent and stable inhibition of HDAC8.
• Compounds 9h and 9m showed significant efficacy specifically in neuroblastoma cells, with minimal effects on other cell lines.
• Inhibition of neuroblastoma cell growth, migration, and induction of apoptosis were observed.
• Increased SMC3 acetylation confirmed target engagement by the inhibitors.

Conclusions:

• The designed [1,2,4]Triazolo[4,3-a]quinoline derivatives are effective non-hydroxamate HDAC8 inhibitors.
• These compounds show strong potential as therapeutic agents for neuroblastoma treatment.
• Further development of these inhibitors is warranted for clinical application.